ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home / Trades / #385413

Flowers Lee bought HCWB

July 29, 2026 · Form 4 insider transaction

Flowers Lee bought 7,736 shares of HCW Biologics Inc. at $2.58 per share, a transaction worth $20.0K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
7,736
Price
$2.58
Total value
$20.0K
InsiderFlowers Lee
Role—
CompanyHCW Biologics Inc. (HCWB)
SecurityCommon Stock
Transaction codeP — Open-market purchase
Transaction dateJuly 29, 2026
Filing dateJuly 31, 2026
Shares owned after8,691
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.

View the original Form 4 on SEC EDGAR